Title: Effect of CXL in Keratoconus patients

Authors: Dr Md. Kamrul Islam, Dr Md. Nasir Uddin, Dr AKM Shamsuddin

 DOI: https://dx.doi.org/10.18535/jmscr/v8i6.121

Abstract

Objective: In this study our main goal is to evaluate the effect of CXL in Keratoconus patients in Bangladesh.

Method: This retrospective observational type of study was conducted among 80 patients who fulfilled criteria from tertiary medical college and hospital from February 2019 to February 2020.

Results: During the study, 60% patients were male, which was 20% higher than female. Also, skin allergies in (26%), symptomatic ocular allergies in (22%), and asthma in (14%) patients. Only (6%) patients had positive family history of keratoconus. The mean preoperative spherical refractive error was -1.46 ± 2.31 diopters, the mean cylinder was -3.70 ± 1.81 diopters and mean spherical equivalent (SE) was -3.24 ± 2.44 diopters. Postoperatively the mean sphere was -1.35± 2.22 diopters, the mean cylinder was -3.11 ± 1.86 diopters and the mean SE was -2.91 ± 2.40 diopters.

Conclusion: From our study we can conclude that, CXL improves visual acuity and reduces maximal keratometry values in KC patients effectively as in younger patients. It also could be considered as a promising first line treatment for most patients with progressive KCN.

Keywords: Keratoconus (KCN), cornel collagen cross linking (CXL),corneal condition.

References

  1. Bawazeer AM, Hodge WG, Lorimer B. Atopy and keratoconus: a multivariate analysis. Br J Ophthalmol. 2000;84:834–836. [PMC free article] [PubMed] [Google Scholar]
  2. Szczotka LB, Barr JT, Zadnik K the CLEK Study Group. A summary of the findings from the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) study. Optometry. 2001;72:574–587. [PubMed] [Google Scholar]
  3. Weed KH, McEwen CJ, Giles T, Low J, McGhee CNJ. The Dundee University Scottish Keratoconus Study: Demographics, corneal signs, associated diseases, and eye rubbing. Eye (Lond) 2008;22:534–541. [PubMed] [Google Scholar]
  4. Jonas J, Nangia V, Matin A, Kulkarni M, Bhojwani K. Prevalence and associations of keratoconus in rural maharashtra in central India: the central India eye and medical study. Am J Ophthalmol. 2009;148:760–765. [PubMed] [Google Scholar]
  5. Georgiou T, Funnell CL, Cassels-Brown A, O’Conor R. Influence of ethnic origin on the incidence of keratoconus and associated atopic disease in Asians and white patients. Eye (Lond) 2004;18:379–383. [PubMed] [Google Scholar]
  6. Pearson AR, Soneji B, Sarvananthan N, Sandford-Smith JH. Does ethnic origin influence the incidence or severity of keratoconus? Eye (Lond) 2000;14:625–628. [PubMed] [Google Scholar]
  7. O’Brart DP, et al. “Corneal Cross-linking to Halt the Progression of Keratoconus and Corneal Ectasia: Seven- Year Follow-up.” American Journal of Ophthalmology Vol. 160, No. 6, 2015, pp. 1154-63.
  8. Saffarian L, et al. “Corneal Crosslinking for Keratoconus in Iranian Patients: Outcomes at 1 year following treatment.” Middle East African Journal of Ophthalmology Vol. 17, No. 4, 2010, pp. 365-68.
  9. O’Brart DP, et al. “A randomised, prospective study to investigate the efficacy of riboflavin/ultraviolet A (370 nm) corneal collagen cross-linkage to halt the progression of keratoconus.” British Journal of Ophthalmology Vol. 95, No. 11, 2011, pp. 1519-24.
  10. Wittig-Silva C, et al. “A randomized, controlled trial of corneal collagen cross-linking in progressive keratoconus: three-year results.” Ophthalmology Vol. 121, No. 4, 2014, pp. 812-21.
  11. O’Brart DP, et al. “Long-term follow-up of riboflavin/ultraviolet A (370 nm) corneal collagen cross-linking to halt the progression of keratoconus.” British Journal of Ophthalmology Vol. 97, No. 4, 2013, pp. 433-37.
  12. Wagner H, Barr JT, Zadnik K. Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study: methods and findings to date. Cont Lens Anterior Eye. 2007;30 (4:223–232.

Corresponding Author

Dr Md. Kamrul Islam

Assistant Professor, (Eye), Patuakhali Medical College, Patualhali, Bangladesh